OpGen (OPGN) Competitors $0.94 -0.15 (-13.38%) As of 01/31/2025 03:48 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends OPGN vs. ENZ, CCM, BRTX, MRAI, KDLY, OTRK, BGLC, MGRX, ATPC, and DHACShould you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Enzo Biochem (ENZ), Concord Medical Services (CCM), BioRestorative Therapies (BRTX), Marpai (MRAI), Kindly MD (KDLY), Ontrak (OTRK), BioNexus Gene Lab (BGLC), Mangoceuticals (MGRX), Agape ATP (ATPC), and Digital Health Acquisition (DHAC). These companies are all part of the "healthcare" industry. OpGen vs. Enzo Biochem Concord Medical Services BioRestorative Therapies Marpai Kindly MD Ontrak BioNexus Gene Lab Mangoceuticals Agape ATP Digital Health Acquisition Enzo Biochem (NYSE:ENZ) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Which has more volatility & risk, ENZ or OPGN? Enzo Biochem has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, OpGen has a beta of -0.49, suggesting that its stock price is 149% less volatile than the S&P 500. Does the MarketBeat Community believe in ENZ or OPGN? OpGen received 89 more outperform votes than Enzo Biochem when rated by MarketBeat users. However, 54.08% of users gave Enzo Biochem an outperform vote while only 53.09% of users gave OpGen an outperform vote. CompanyUnderperformOutperformEnzo BiochemOutperform Votes21254.08% Underperform Votes18045.92% OpGenOutperform Votes30153.09% Underperform Votes26646.91% Is ENZ or OPGN more profitable? Enzo Biochem has a net margin of -75.34% compared to OpGen's net margin of -1,140.36%. OpGen's return on equity of 0.00% beat Enzo Biochem's return on equity.Company Net Margins Return on Equity Return on Assets Enzo Biochem-75.34% -7.96% -5.49% OpGen -1,140.36%N/A -287.58% Which has preferable valuation and earnings, ENZ or OPGN? Enzo Biochem has higher revenue and earnings than OpGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnzo Biochem$31.91M0.98-$26.08MN/AN/AOpGen$3.42M2.31-$32.67MN/AN/A Does the media refer more to ENZ or OPGN? In the previous week, Enzo Biochem and Enzo Biochem both had 1 articles in the media. OpGen's average media sentiment score of 0.00 beat Enzo Biochem's score of -0.55 indicating that OpGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enzo Biochem 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative OpGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of ENZ or OPGN? 36.9% of Enzo Biochem shares are owned by institutional investors. Comparatively, 2.7% of OpGen shares are owned by institutional investors. 11.4% of Enzo Biochem shares are owned by insiders. Comparatively, 43.8% of OpGen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryEnzo Biochem beats OpGen on 7 of the 12 factors compared between the two stocks. Get OpGen News Delivered to You Automatically Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPGN vs. The Competition Export to ExcelMetricOpGenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.89M$3.14B$5.56B$9.11BDividend YieldN/A17.12%5.31%3.98%P/E RatioN/A16.7189.9918.25Price / Sales2.31341.101,245.8384.55Price / CashN/A418.9945.9637.70Price / Book-0.085.375.124.71Net Income-$32.67M-$33.85M$111.09M$224.24M7 Day Performance-21.38%-0.19%0.09%-0.25%1 Month Performance58.57%2.46%3.20%1.48%1 Year Performance-72.15%17.61%25.75%21.06% OpGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPGNOpGenN/A$0.94-13.4%N/A-72.2%$9.34M$3.42M0.00100Analyst ForecastNews CoverageENZEnzo Biochem0.7327 of 5 stars$0.65-0.6%N/A-52.4%$33.90M$31.91M0.00520Gap UpCCMConcord Medical Services0.4569 of 5 stars$4.26-10.9%N/A-31.4%$18.49M$75.69M0.00970Short Interest ↑BRTXBioRestorative Therapies3.487 of 5 stars$2.30-0.9%$18.00+682.6%+46.0%$15.92M$150,000.00-1.507Short Interest ↑MRAIMarpaiN/A$0.96-4.1%$6.00+525.8%-18.0%$13.69M$34.87M-0.36150Gap DownKDLYKindly MDN/A$1.26-6.0%N/AN/A$7.54MN/A0.00N/AShort Interest ↓Gap UpOTRKOntrak3.7544 of 5 stars$1.73+0.6%$45.00+2,501.2%-49.1%$7.30M$12.74M-0.16250Short Interest ↓BGLCBioNexus Gene Lab0.3567 of 5 stars$0.40+12.6%N/A-13.2%$7.15M$9.77M0.0030MGRXMangoceuticals1.5726 of 5 stars$2.78-7.0%N/A-96.3%$6.91M$755,000.00-0.483ATPCAgape ATP0.2112 of 5 stars$1.52-7.3%N/A-89.1%$6.07M$1.43M-2.0840Short Interest ↑Gap DownDHACDigital Health AcquisitionN/A$1.64+4.5%N/A-86.2%$5.91MN/A0.002,021News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies ENZ Competitors CCM Competitors BRTX Competitors MRAI Competitors KDLY Competitors OTRK Competitors BGLC Competitors MGRX Competitors ATPC Competitors DHAC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OPGN) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
